Navigation Links
Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
Date:4/7/2009

will be available immediately by prescription at retail pharmacies nationwide.

In addition to RAPAFLO(TM), Watson will soon launch GELNIQUE, the first and only topical gel for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Watson also has submitted a New Drug Application for a 6-month formulation of Trelstar(R) (triptorelin pamoate), a luteinizing hormone releasing hormone (LHRH) agonist for the palliative treatment of advanced prostate cancer. Watson anticipates that FDA will take action on this application in the third quarter 2009.

About RAPAFLO

RAPAFLO(TM) is an effective, selective alpha-1 adrenergic receptor antagonist that binds with high affinity to the alpha 1a receptors concentrated in the prostate, bladder base and neck and seminal vesicles. It regulates the receptors, causing smooth muscles in these tissues to relax, resulting in improved urine flow and a reduction in BPH symptoms. The binding affinity for the alpha 1B receptors that regulate smooth muscle relaxation and blood pressure effects is lower, minimizing the potential for side effects.

In two Phase 3 studies, 8 mg once-daily RAPAFLO(TM) taken for 12 weeks resulted in significant and rapid relief of BPH symptoms compared with placebo, as measured by the International Prostate Symptom Score (IPSS). IPSS includes irritative (frequency, urgency, and nocturia), and obstructive (hesitancy, incomplete emptying, intermittency, and weak stream) symptoms. RAPAFLO also has been proven to significantly improve Qmax scores (maximum urine flow rates) as early as two hours following first dose and at 12 weeks of treatment.

In clinical trials, RAPAFLO(TM) also demonstrated minimal electro cardiac effects on the cardiovascular system, without any meaningful prolongation of the QT interval. The most common drug-related side effect was retrograde ejaculation
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
2. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
3. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
4. Watson Launches Generic Biaxin(R) XL
5. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
6. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
7. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
8. Schering-Plough Announces Results of the Early ACS Trial
9. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
10. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
11. Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Pa. , Aug. 3, 2015 ... specialty biotechnology company focused on developing aerosolized KL4 ... live teleconference and webcast at 8:30 a.m. Eastern Time ... management will discuss the 2015 second quarter financial ... company will issue a press release announcing the ...
(Date:8/3/2015)... REDWOOD CITY, Calif., Aug. 3, 2015 AcelRx ... company focused on the development and commercialization of innovative ... a business update and reported financial results for the ... Business highlights include: , On July 23, ... (CHMP) adopted a positive opinion for Zalviso™ for the ...
(Date:8/3/2015)... Diplomat Pharmacy, Inc. (NYSE: DPLO ), the nation,s largest ... June 30, 2015. All comparisons, unless otherwise noted, are to ... Quarter 2015 Highlights include: , Revenue of $808 ... Total prescriptions dispensed of 234,000, an increase of 19% ... EBITDA of $22.7 million, an increase of 287% or $16.8 ...
Breaking Medicine Technology:Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
(Date:8/4/2015)... ... August 04, 2015 , ... Increasingly, patients are ... calling a physician. In an effort to share more and better information with ... Pennsylvania to publicly share patient satisfaction ratings and comments about its doctors and ...
(Date:8/4/2015)... ... August 04, 2015 , ... Discovia, a leading global ... that John Munro, a 15-year veteran of the eDiscovery services industry, has joined ... “I am thrilled to join Discovia at this important point in its evolution,” ...
(Date:8/4/2015)... New York (PRWEB) , ... August 04, 2015 ... ... exceptional dietary supplement manufacturing, label design, product packaging, and fulfillment services, joined over ... Challenge. The event was held on Tuesday, July 28th at Jones Beach ...
(Date:8/4/2015)... Louis, Missouri (PRWEB) , ... August 04, 2015 ... ... Texting (IAT) solutions, today announced that Bruce McCalley joins its executive leadership team ... track record of sales success at technology companies and expanding global markets with ...
(Date:8/4/2015)... ... 04, 2015 , ... Patients are invited to take advantage ... renowned Beverly Hills facelift surgeon , Dr. Paul Nassif. The opportunity to ... to achieve an outer appearance that meets their personal goals. This consultation with ...
Breaking Medicine News(10 mins):Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 3
... Will Earn Decision Resources, Gold Standard for Rheumatoid ... from Decision ResourcesWALTHAM, Mass., Jan. 28 Decision ... advisory firms for pharmaceutical and healthcare issues, finds ... on reducing the signs and symptoms of rheumatoid ...
... Data Show Significant Reduction In Snoring Events, Increase ... 28 AirWare, Inc., maker of Brez premium ... for inside the nose clinically proven to reduce ... bed partner, today announced availability in all Rite ...
... shows that very low amounts of Micromet,s EpCAM-targeting BiTE ... 28 Micromet, Inc. (Nasdaq: MITI ), ... treatment of cancer, inflammation and autoimmune diseases, today announced ... Immunobiology describing in detail the mode of action ...
... BD (Becton, Dickinson and Company) (NYSE: BDX ... first fiscal quarter ended December 31, 2008, representing an increase ... quarter,s growth rate reflects the unfavorable impact from foreign currency ... percentage points. "BD is off to a solid start ...
... Inc. (Pink Sheets: PCIR) today announced it has entered ... spin off its wholly owned subsidiary, Prepaid Tel.com, Inc., ... firm which, once it has gone public, will reward ... company.The agreement with TransPacific Telecom, Inc., the developer of ...
... have delivered the world’s first commercially cloned dog, a 10-week old ... , ... Boca Raton, FL (Vocus) January 28, 2009 -- ... commercially cloned dog, a 10-week old Labrador named Lancey, to Florida ...
Cached Medicine News:Health News:Current and Emerging Therapies Have No Advantage Over Enbrel in Reducing the Signs and Symptoms of Rheumatoid Arthritis 2Health News:Current and Emerging Therapies Have No Advantage Over Enbrel in Reducing the Signs and Symptoms of Rheumatoid Arthritis 3Health News:Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies 2Health News:Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies 3Health News:Brez(R), the First Over-the-Counter, Intranasal Breathing Aid Clinically Proven to Reduce Primary Snoring, Debuts in Rite Aid Pharmacies 4Health News:New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110 2Health News:New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110 3Health News:New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110 4Health News:New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110 5Health News:BD Announces Results for First Fiscal Quarter 2Health News:BD Announces Results for First Fiscal Quarter 3Health News:BD Announces Results for First Fiscal Quarter 4Health News:BD Announces Results for First Fiscal Quarter 5Health News:BD Announces Results for First Fiscal Quarter 6Health News:BD Announces Results for First Fiscal Quarter 7Health News:BD Announces Results for First Fiscal Quarter 8Health News:BD Announces Results for First Fiscal Quarter 9Health News:BD Announces Results for First Fiscal Quarter 10Health News:Prime Companies Reaches Agreement to Spin Off Subsidiary; Shareholders Gain 15 Percent Stake in New Telecommunications Company 2Health News:First Commercially Cloned Dog Delivered to Florida Family 2
For the quantitative in vitro determination of K-glutamyl transferase (K-GT) in serum or plasma....
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
The XCHO method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of cholesterol in serum and plasma....
For the quantitative in vitro determination of alanine aminotransferase in serum or plasma....
Medicine Products: